Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

ABSTRACT:

SUBMITTER: Moreau P 

PROVIDER: S-EPMC4420234 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature